AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 6.6% in January

AstraZeneca PLC (NASDAQ:AZNGet Free Report) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 5,810,000 shares, a decline of 6.6% from the December 31st total of 6,220,000 shares. Based on an average trading volume of 5,530,000 shares, the days-to-cover ratio is presently 1.1 days.

AstraZeneca Trading Up 0.3 %

AZN opened at $66.85 on Friday. The firm has a market cap of $207.26 billion, a price-to-earnings ratio of 35.18, a PEG ratio of 1.19 and a beta of 0.49. The company has a current ratio of 0.79, a quick ratio of 0.60 and a debt-to-equity ratio of 0.60. AstraZeneca has a 12 month low of $61.73 and a 12 month high of $76.56. The stock has a fifty day moving average price of $66.40 and a 200-day moving average price of $66.85.

AstraZeneca (NASDAQ:AZNGet Free Report) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.84 by $0.03. The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $11.55 billion. AstraZeneca had a return on equity of 30.30% and a net margin of 13.10%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.84 EPS. As a group, equities research analysts anticipate that AstraZeneca will post 3.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AZN. First Affirmative Financial Network increased its position in AstraZeneca by 2.9% during the 3rd quarter. First Affirmative Financial Network now owns 5,495 shares of the company’s stock valued at $372,000 after buying an additional 155 shares in the last quarter. Wrapmanager Inc. increased its position in AstraZeneca by 4.1% during the 2nd quarter. Wrapmanager Inc. now owns 3,962 shares of the company’s stock valued at $284,000 after buying an additional 157 shares in the last quarter. Private Trust Co. NA increased its position in AstraZeneca by 7.0% during the 2nd quarter. Private Trust Co. NA now owns 2,479 shares of the company’s stock valued at $177,000 after buying an additional 162 shares in the last quarter. Clearstead Advisors LLC increased its position in AstraZeneca by 15.5% during the 3rd quarter. Clearstead Advisors LLC now owns 1,209 shares of the company’s stock valued at $82,000 after buying an additional 162 shares in the last quarter. Finally, Center for Financial Planning Inc. grew its stake in AstraZeneca by 32.9% during the 3rd quarter. Center for Financial Planning Inc. now owns 671 shares of the company’s stock valued at $45,000 after purchasing an additional 166 shares during the last quarter. 15.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Morgan Stanley assumed coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. StockNews.com started coverage on AstraZeneca in a research report on Thursday, October 5th. They set a “strong-buy” rating for the company. Finally, HSBC started coverage on AstraZeneca in a research report on Monday, December 18th. They set a “buy” rating for the company. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $80.00.

Get Our Latest Analysis on AZN

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.